- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
European Commission Approves Stelara® (Ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn’s Disease
First Interleukin (IL)-12/23 Inhibitor Licensed For Crohn’s Disease
New Therapeutic Vaccine Approach in Non-Human Primates Shows Potential as Functional Cure for HIV-1
Pre-clinical data published in Nature shows approach reduced hard-to-reach reservoirs of HIV-like virus
ASH 2016: Janssen to Present 43 Abstracts with Data on Ibrutinib, Daratumumab and Other Compounds Showing Treatment Advances in Malignant and Non-Malignant Hematologic Conditions
Key data include Phase 2 five-year follow-up data for ibrutinib in CLL and updated Phase 3 depth of response data for daratumumab in combination with standard of care therapies for patients with multiple myeloma who have received at least one prior therapy
Janssen to Present Data Across Broad Rheumatology Portfolio and Immunology Pipeline at the 2016 American College of Rheumatology Meeting
Twenty-Eight Janssen Data Presentations Demonstrate Commitment to Innovation in Rheumatology
Janssen Partners with University of Pennsylvania and Castleman Disease Collaborative Network to Launch First Global Patient Registry for Castleman Disease
Registry Aims to Improve Care and Accelerate Research for Rare Disorder by Putting Power in the Hands of Patients
Janssen Therapeutics Announces Funding in Support of Improved Retention in Care and Access to Treatment for Blacks and African Americans Living with HIV in Southern United States and other Rural Areas
Award Funding Extends Company’s Ongoing Commitment to Supporting Underserved Communities in the United States